Internal Medicine Doctors in Fort Sill, OK Accepting Medicare

7 Internal Medicine doctors found. Showing 1 - 7

Randall Lee Jenkins, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4303 Pitman & Thomas Ave., Fort Sill, OK 73503 Phone: 580-353-1131    Fax: 580-353-0340

Dr. Rodrigo Alba Mariano, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4301 Mow Way Rd, Reynolds Army Community Hospital, Fort Sill, OK 73503 Phone: 580-458-2246    Fax: 580-458-3433

Dr. Ahmed Abou Elmagd, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4303 Pitman, Fort Sill, OK 73503 Phone: 580-585-5600    Fax: 580-585-5703

Dr. Jeremy Bouwhuis, D.O. Internal Medicine Medicare: Medicare Enrolled Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 833-286-3732

Susan Kathleen Drake, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4301 Mow-way Road, Fort Sill, OK 73503 Phone: 580-458-2246    Fax: 580-458-3411

Dr. Elizabeth G. K. Akaka, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 580-558-2200

Imran Akram Rao, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4303 Pitman And Thomas, Fort Sill, OK 73503 Phone: 580-353-1131    Fax: 580-355-9094

News Archive

We can consciously control neurons inside our head

Every day our brains are flooded by stimulation - sounds, sights and smells. At the same time, we are constantly engaged in an inner dialogue, ruminating about the past, musing about the future. Somehow the brain filters all this input instantly, selecting some things for long- or short-term storage, discarding others and focusing in on what's most important at any given instant.

Promising clinical trial for Progeria "premature aging" disease

One of the fastest translations of a basic research discovery into a promising clinical trial for an "untreatable" and fatal disorder will be discussed publicly for the first time by the key players in this remarkable research story, on Sunday, Dec. 14, at the American Society for Cell Biology (ASCB)'s annual meeting in San Francisco.

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Australian oncology drug development company Novogen Limited and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

Targeted nanoparticles deliver therapeutic DNA to cancer cells

Given that cancer is a disease caused by gene mutations, cancer researchers have been striving to develop gene therapies aimed at correcting these mutations. However, these efforts have been hobbled by the difficulty in safely and efficiently delivering anticancer genes to tumors. Nanoparticles, however, may solve these delivery issues, and two recently published studies, using two different types of nanoparticles, lend credence to that hypothesis.

Read more Medical News

› Verified 8 days ago